Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions.

ABSTRACT: Digestive well-differentiated grade 3 neuroendocrine tumors (NET G-3) have been clearly defined since the 2017 World Health Organization classification. They are still a rare category lacking specific data and standardized management. Their distinction from other types of neuroendocrine neoplasms (NEN) not only lies in morphology but also in genotype, aggressiveness, functional imaging uptake, and treatment response. Most of the available data comes from pancreatic series, which is the most frequent tumor site for this entity. In the non-metastatic setting, surgical resection is recommended, irrespective of grade and tumor site. For metastatic NET G-3, chemotherapy is the main first-line treatment with temozolomide-based regimen showing more efficacy than platinum-based regimen, especially

SUBMITTER: Pellat A 

PROVIDER: S-EPMC8158108 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature